BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8735790)

  • 1. Design and assessment of clinical trials on continuous infusion.
    Schulman S; Martinowitz U
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S7-9. PubMed ID: 8735790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and indications for continuous infusion of antihemophilic factor (factor VIII).
    Goldsmith JC
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S3-6. PubMed ID: 8735789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous infusion of factor VIII for surgery and major bleeding.
    Hay CR; Doughty HI; Savidge GF
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII pharmacokinetics: intermittent infusion versus continuous infusion.
    Morfini M; Messori A; Longo G
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S11-4. PubMed ID: 8735791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic infusion regimens in the management of hemophilia.
    Ljung RC
    Thromb Haemost; 1999 Aug; 82(2):525-30. PubMed ID: 10605746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Family issues in continuous infusion therapy with factor VIII.
    Manco-Johnson MJ
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S21-5. PubMed ID: 8735793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous infusion of coagulation factors: current opinion.
    Batorova A; Martinowitz U
    Curr Opin Hematol; 2006 Sep; 13(5):308-15. PubMed ID: 16888434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis and continuous infusion for hemophilia: can we afford it?
    Aledort LM; Bohn RL
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S35-7. PubMed ID: 8735795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of pumps for continuous infusion of coagulation factor concentrates: what are the options?
    Martinowitz U; Schulman S
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S27-33. PubMed ID: 8735794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of clinical studies with recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Pennington JE; Schwartz RS
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):27-8. PubMed ID: 1908123
    [No Abstract]   [Full Text] [Related]  

  • 11. Single-dose pharmacokinetics of porcine factor VIII (Hyate C).
    Hermans C; Owens D; Longo G; Morfini M; Lee CA
    Thromb Haemost; 2002 Feb; 87(2):352-3. PubMed ID: 11858504
    [No Abstract]   [Full Text] [Related]  

  • 12. Stability of ADVATE, Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusion.
    Fernandez M; Yu T; Bjornson E; Luu H; Spotts G
    Blood Coagul Fibrinolysis; 2006 Apr; 17(3):165-71. PubMed ID: 16575253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hemophilia A with factor VIII inhibitor].
    Shima M
    Rinsho Ketsueki; 2003 Feb; 44(2):90-101. PubMed ID: 12692981
    [No Abstract]   [Full Text] [Related]  

  • 14. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regimens of factor VIII administration--continuous infusion vs. bolus.
    Berntorp E
    Haematologica; 2000 Oct; 85(10 Suppl):69-71; discussion 71-2. PubMed ID: 11187875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous infusion of monoclonal antibody-purified factor VIII.
    Weinstein RE; Bona RD; Rickles FR
    Am J Hematol; 1991 Mar; 36(3):211-2. PubMed ID: 1899966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis.
    den Uijl IE; Fischer K
    Thromb Haemost; 2008 May; 99(5):965; author reply 966-8. PubMed ID: 18449430
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics of factor VIII in hemophilia A patients assessed by frequency response method.
    Durisová M; Dedík L; Bátorová A; Sakalová A; Hedera J
    Methods Find Exp Clin Pharmacol; 1998 Apr; 20(3):217-26. PubMed ID: 9646284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of B-domain deleted recombinant factor VIII (ReFacto) stability during simulated continuous infusion administration.
    Neidhardt E; Koval R; Burke E; Warne N
    Haemophilia; 2005 Jul; 11(4):319-25. PubMed ID: 16011582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
    Lusher JM
    Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.